Loading
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML).
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/